Tactical approaches to the treatment of arterial hypertension in the European part of the Russian Federation. EPOHA study 2017
https://doi.org/10.18087/cardio.n408
Abstract
Aim. Analysis of antihypertensive treatment among different groups of patients with arterial hypertension from “EPOCHA” study 2017. Materials and methods. EPOCHA study is a representative sample of the European part of the Russian Federation was created in 2002 and re-examined in 2017. Results. 34.6% of the effectively treated (ET) patients had one antihypertensive drug and 32,2% of the ineffective treatment (IT) patients, p=0.16. Two-component antihypertensive therapy was 45.9% and 44.9%, respectively, p=0.56. Three antihypertensive drugs had 17.9% of the ET patients and 20.7% of the IT patients, p=0.05. Four antihypertensive drugs had 1.6% of the ET patients and 2.2% of the IT patients. The frequency of use of renin-angiotensin-aldosterone system blockers in the group of ET patients was 85.0%, which was significantly lower than 91.6% in the group of IT patients, р<0.0001. Conclusion. EPOCHA study shows that structure of antihypertensive therapy does not differ between ET and IT patients what is caused lack of medical supervision for patients with hypertension in real clinical practice.
About the Author
Yu. V. Badin
Privolzhsky Research Medical University
Russian Federation
Minin and Pozharsky square 10/1, Nizhny Novgorod 603950
Russian Federation
Minin and Pozharsky square 10/1, Nizhny Novgorod 603950
References
1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339
2. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–324. DOI: 10.1161/HYP.0000000000000066
3. The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine. 2015;373(22):2103–16. DOI: 10.1056/NEJMoa1511939
4. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 2016; 374(21):2009–20. DOI: 10.1056/NEJMoa1600175
5. Gee ME, Campbell NRC, Gwadry-Sridhar F, Nolan RP, Kaczorowski J, Bienek A et al. Antihypertensive Medication Use, Adherence, Stops, and Starts in Canadians with Hypertension. Canadian Journal of Cardiology. 2012;28(3):383–9. DOI: 10.1016/j.cjca.2012.01.014
6. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS data brief. 2013;133:1–8. PMID: 24171916
7. Friedman O, McAlister FA, Yun L, Campbell NRC, Tu K. Antihypertensive Drug Persistence and Compliance Among Newly Treated Elderly Hypertensives in Ontario. The American Journal of Medicine. 2010;123(2):173–81. DOI: 10.1016/j.amjmed.2009.08.008
8. Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. European Heart Journal. 2011;32(17):2143–52. DOI: 10.1093/eurheartj/ehr080
9. Chow CK. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and LowIncome Countries. JAMA. 2013;310(9):959–68. DOI: 10.1001/jama.2013.184182
10. Mareev V.Yu., Belenkov Yu.N., Ageev F.T., Fomin I.V., Chochlov R.A., Galiavich A.S. et al. The first results of Russian epidemiological studies with CHF (EPOCHA-CHF). Russian Heart Failure Journal. 2003;4 (1):17–8.
11. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal. 2016;37(29):2315–81. DOI: 10.1093/eurheartj/ehw106
12. Mozheyko M, Eregin S, Vigdorchik A, Tobe S, Campbell N, Riahi F et al. Changes in Hypertension Treatment in the Yaroslavl Region of Russia: Improvements Observed Between 2 Cross-Sectional Surveys. The Journal of Clinical Hypertension. 2013;15(12):918–24. DOI: 10.1111/jch.12214
13. Morozova T.E., Andrushchishina T.B., Yudina I.Yu. Комбинированная фармакотерапия артериальной гипертонии. Обзор фиксированных комбинаций антигипертензивных препаратов. Systemic Hypertension. 2016;13(3):58–63.
14. Leonova M.V., Belousov Yu.B. Results of pharmacoepidemiological study of arterial hypertension in Russia (Pythagoras). Problems of standardization in health care. 2005;4:12–20.
15. Ali MA, Rizvi S, Syed BA. Trends in the market for antihypertensive drugs. Nature Reviews Drug Discovery. 2017;16(5):309–10. DOI: 10.1038/nrd.2016.262
Review
For citations:
Badin Yu.V. Tactical approaches to the treatment of arterial hypertension in the European part of the Russian Federation. EPOHA study 2017. Kardiologiia. 2019;59(11S):77-84. (In Russ.) https://doi.org/10.18087/cardio.n408
Views:
764
Email this article 
Post a Comment 
